SLV-324 / Solve Therap - LARVOL DELTA

Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors (Businesswire) - "This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million....Financing accelerates development of clinical-stage assets SLV-154 and SLV‑324, both featuring Solve’s CloakLink linker technology."

Financing • Solid Tumor